Moteur de recherche d’entreprises européennes
Financement de l’UE (5 998 603 €) : Développement d’une approche de biomédecine systémique pour l’identification des risques, la prévention et le traitement du diabète de type 2 Hor 01/01/2016 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Développement d’une approche de biomédecine systémique pour l’identification des risques, la prévention et le traitement du diabète de type 2
Type 2 diabetes (T2D) is a major public health problem, affecting 55 million European citizens. T2D ensues in individuals who develop a progressive pancreatic beta cell failure. T2D probably comprises a heterogeneous group of diseases. A new molecular taxonomy of T2D is essential for the development of medical care that is predictive, preventive and personalized. Currently available T2D therapies are not disease modifying: they treat hyperglycaemia without addressing its underlying cause, i.e. beta cell failure. In this proposal we seek to identify pathogenic molecular events that operate in the diseased tissue, i.e. the failing human beta cell, at their true level of complexity. T2DSystems will accomplish this ambitious goal by integrating human islet genetic and epigenetic data with disease-relevant environmental perturbations, metabolomics and functional studies, and use this knowledge to identify distinct human islet phenotypes in subgroups of patients. In closely interacting work packages, we will achieve the following goals: • Compile and expand existing European bio-banks and datasets to create the Translational human pancreatic Islet Genotype tissue-Expression Resource (TIGER), a T2D systems biomedicine resource of unprecedented scale; • Develop large-scale data analysis tools and both data driven and mechanistic probabilistic modelling frameworks to exploit TIGER towards system level biological insight; • Translate these findings to identify stratified beta cell phenotypes in human cohorts. This will provide understanding of beta cell pathophysiology in vivo and enable stratified prevention and therapeutics. T2DSystems will enable the development of personalized diagnostic tests, taking into account individual environmental and genetic risk factors. The newly identified molecular disease mechanisms will provide the basis for development of novel therapies and for patient stratification to test individualized therapies.
| A2F Associates Ltd. | 186 150 € |
| Barcelona Supercomputing Center Centro Nacional de Supercomputacion | 451 961 € |
| Consorcio Centro de Investigacion Biomedica en Red M.P | 0,00 € |
| Fundacio Centre de Regulacio Genomica | 179 237 € |
| Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi i Sunyer | 402 830 € |
| Hospital Clinic de Barcelona | 0,00 € |
| Imperial College of Science Technology and Medicine | 118 179 € |
| Kobenhavns Universitet | 488 493 € |
| Lunds Universitet | 589 668 € |
| Sirion Biotech GmbH | 454 500 € |
| The Chancellor, Masters and Scholars of the University of Oxford | 633 419 € |
| Universita Di Pisa | 517 723 € |
| Universite Libre de Bruxelles | 1 504 958 € |
| ZS Associates AS | 471 486 € |
https://cordis.europa.eu/project/id/667191
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.